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REVIEW
Abstract: COPD is a progressive illness with worldwide impact. Patients invariably reach a
point at which they require palliative interventions. Dyspnea is the most distressing symptom
experienced by these patients; when not relieved by traditional COPD management strategies
it is termed “refractory dyspnea” and palliative approaches are required. The focus of care
shifts from prolonging survival to reducing symptoms, increasing function, and improving
quality of life. Numerous pharmacological and non-pharmacological interventions can achieve
these goals, though evidence supporting their use is variable. This review provides a summary
of the options for the management of refractory dyspnea in COPD, outlining currently available
evidence and highlighting areas for further investigation. Topics include oxygen, opioids,
psychotropic drugs, inhaled furosemide, Heliox, rehabilitation, nutrition, psychosocial support,
breathing techniques, and breathlessness clinics.
Keywords: chronic obstructive pulmonary disease (MeSH), dyspnea (MeSH), palliative care
(MeSH), analgesics, opioid (MeSH), oxygen (MeSH)
Introduction
COPD is an international health problem with a worldwide prevalence of at least
9.34/1000 in men and 7.33/1000 in women (1990 estimate) (Murray and Lopez 1996a,
1996b). It is the fourth leading cause of death worldwide (WHO 2000). The burden
of COPD is expected to increase, such that by 2020, it will be the fifth leading cause
of lost disability-adjusted life years worldwide (Murray and Lopez 1996a, 1996b).
The 2001 Global Strategy for the Diagnosis, Management, and Prevention of
COPD (GOLD) guidelines recommend a step-wise approach to care as lung function
declines and patients become more symptomatic with the addition of therapeutic
interventions including bronchodilators (short- and long-acting), anti-cholinergic
agents, pulmonary rehabilitation, inhaled glucocorticoids, and oxygen (Pauwels et
al 2001). While this strategy has improved management, the only intervention that
slows progression of disease is smoking cessation, as has been documented in the
Lung Health Study I, EUROSCOP, the Copenhagen City Lung Study, and the ISOLDE
trial (Burrows et al 1987; Pauwels et al 1999). Additionally, while oxygen improves
survival in hypoxemic patients with COPD, survival is no different from similar
patients with no hypoxemia (Murray and Nadel 2000). As a result, COPD remains a
progressive, incurable illness.
Predicting survival and timing of disability in COPD is difficult. Lung function
decreases with age and age is inversely proportional to survival. Decline in lung
function is not always continuous. The course of COPD is punctuated by acute
exacerbations with deterioration in lung function that is less likely to completely
resolve as disease progresses (Burrows 1990). Exacerbations increase in frequency
as lung function declines and some individuals experience a more rapid deterioration
than others. These “rapid decliners” have been identified in prospective studies but
it is not clear what sets them apart (Gottlieb et al 1996). Other variables that influence
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mortality include forced expiratory volume in one second
(FEV1), nutritional status, and associated co-morbid disease
(Melbostad et al 1997). Mortality increases as FEV1 declines
(Mannino et al 2003), although mortality is best predicted
by a multifactorial staging system that includes factors in
addition to FEV1 (Celli et al 2004). Overall, patients with
COPD follow a trajectory of illness characterized by
intermittent worsening followed by improvements in
performance status with an overall progression towards
complete disability and then death (Lunney et al 2002, 2003)
(Figure 1).
As time passes, quality of life (QOL) diminishes, most
often as a result of increasing dyspnea that eventually
becomes completely disabling. Conventional methods of
alleviating dyspnea by modifying the disease begin to fail
and it becomes more difficult to optimize comfort. Care of
these patients is made all the more difficult by the challenge
in identifying those that are “end-stage” and/or would derive
benefit from palliative interventions.
Need for dyspnea management
and palliative care
There is increasing interest in identifying COPD patients
who would benefit from palliative interventions and
palliative care (Skilbeck et al 1998; Gore et al 2000;
Edmonds et al 2001). The studies are limited by the lack of
a clear definition of “end-stage” COPD but do uncover
important issues. Skilbeck et al (1998) looked at 63 patients
with COPD who were over the age of 55 and had been
admitted to the hospital with an exacerbation in the
preceding 6 months. There were high levels of morbidity
and significant functional limitations. Ninety-five percent
of patients reported that breathlessness was their most
significant debilitating symptom, with 60% indicating the
highest severity level on the scale. Other symptoms causing
disability included pain, fatigue, difficulty sleeping, and
thirst. Decreased physical, social, and emotional functioning
were also described. The authors concluded that COPD
patients had a high burden of poorly controlled symptoms,
most likely as a result of a focus on crisis intervention with
management of acute exacerbations as opposed to continued
improvement in baseline functioning.
Two subsequent studies looked at the care of “end-stage”
COPD patients as compared with the care of patients with
lung cancer. Gore et al (2000) studied 50 patients over age
60 with COPD (defined as FEV1 <0.75 L and at least one
admission for hypercapneic respiratory failure) and 50
patients over age 60 with inoperable non-small cell lung
cancer. The study assessed QOL by several measures as well
as the quantity and quality of medical and social care
received. All data were obtained by a single interviewer.
Patients with COPD had consistently lower (ie, worse)
scores on the MOS Short Form-36 Health Survey (SF-36)
than patients with lung cancer on all subscales (p≤0.05) with
the exception of those measuring emotional and physical
roles. COPD patients also scored higher (ie, worse) than
lung cancer patients on the both the depression (10.18 [SD
3.95] vs 7.22 [SD 5.16], p<0.01) and anxiety (11.44 [SD
4.76] vs 7.20 [SD 5.25], p<0.0001) subscales of the Hospital
Anxiety and Depression Scale (HADS). Finally, 82% of
COPD patients were housebound, compared with 36% of
those with lung cancer. Despite these findings, none of the
COPD patients had received or been offered specialist
palliative care (Gore et al 2000). Some methodological flaws
weaken these results (Hill and Muers 2000). There were
more females than males in the COPD group; female sex is
associated with higher levels of symptomatology and lower
health status (van Wijk and Kolk 1997) as well as higher
scores on the HADS (Aass et al 1997). Additionally, the
lung cancer patients were a particularly well group whose
survival exceeded the typical median survival for such
patients in the UK (Hill and Muers 2000). Even in light of
these discrepancies, the data produced by Gore et al (2000)
support the view that there is a need for better palliative
Figure 1 The trajectory of illness of COPD follows a progressive course with
declines in function alternating with periods of improvement. As the disease
progresses, the focus of care shifts from life-prolonging therapies to palliative
interventions aimed at reducing symptoms, improving function, and improving
quality of life. Reprinted from Lunney JR, Lynn J, Hogan C. 2002. Profiles of older
medicare decedents. J Am Geriatr Soc, 50:1108–12. Copyright © 2002 with
permission from Blackwell Publishing Ltd.International Journal of COPD 2006:1(3) 291
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care for patients with COPD. These data are in agreement
with those of Skilbeck et al (1998) and were further
supported by a later study published by Edmonds et al
(2001).
Edmonds et al (2001) looked at the needs of patients
with chronic lung disease or lung cancer in their final year
of life as reported by a surrogate (relative, friend, or
caregiver). Patients with COPD had troublesome symptoms,
including pain, cough, anorexia, mouth problems, and
insomnia. Breathlessness was most common, with 94% of
respondents reporting this symptom during the final year
of life and 76% rating it as “very distressing.” This contrasts
with the lung cancer patients, 78% of whom reported
breathlessness (p<0.001) with 60% describing it as “very
distressing” (p=0.024). COPD patients had significantly
more frequent (p<0.001) and severe (p<0.024)
breathlessness than the lung cancer group. Similar to the
findings of Gore et al (2000), patients with lung cancer in
the Edmonds et al (2001) study were more likely to have
received hospice care (30%) as compared with those with
COPD (0%, p<0.001).
Together, these data highlight that the symptoms of
patients with COPD are at least as severe as those of patients
with lung cancer and that these patients would benefit from
better symptom management, particularly in the area of
dyspnea. Despite the degree of symptomatology, COPD
patients less frequently access palliative care.
Definition and mechanisms of
dyspnea
Dyspnea is a symptom that is difficult to understand and
difficult to define, for both physicians and patients. The
experience of dyspnea is the combination of a sensation
involving activation of neural pathways and a perception
on the part of the patient (ATS 1999). Descriptions of
dyspnea vary widely and depend, at least in part, on a
patient’s underlying disease, ethnic–racial background,
previous experiences, and emotional state. In an attempt
to incorporate each of these ideas, an American Thoracic
Society consensus panel proposed that dyspnea is “a
subjective experience of breathing discomfort that
consists of qualitatively distinct sensations that vary in
intensity. The experience derives from interactions among
multiple physiological, psychological, social, and
environmental factors, and may induce secondary
physiological and behavioral responses” (ATS 1999 p
322).
The pathophysiological mechanisms that govern the
development of dyspnea are poorly understood. Dyspnea
seemingly results from a mismatch of respiratory motor
activity and incoming afferent activity, including
information from chemo-, vagal, mechano-, pulmonary
stretch, and muscle receptors (ATS 1999). The interaction
between these individual components is only starting to be
understood and there are clearly situations that cannot be
defined by looking at only these factors. For example,
increases in PaCO2 plus decreases in PaO2 and/or pH detected
by peripheral chemoreceptors result in dyspnea. However,
not all patients with abnormal blood gases experience
dyspnea and many dyspneic patients have normal blood
gases (Mountain et al 1978; Stulbarg et al 1989; Kikuchi et
al 1994).
Researchers have tried to define the key parameters of
breathlessness. Fifteen years ago, Simon and colleagues tried
to look at correlates of dyspnea with underlying induced
pathophysiology in normal volunteers (Simon et al 1989),
and in disease pathophysiology in people with established
single causes of dyspnea (Simon et al 1990). There were
some clusters defined. A decade later, that idea was further
developed by Harver et al (2000) in their work which defined
three key domains of breathlessness: depth and frequency
of breathing, perceived urge of need to breathe, and difficulty
breathing and phase of respiration.
Goals of palliative interventions
for intractable dyspnea: relief of
breathlessness and improving
function
Patients often complain of dyspnea that seems out of
proportion to apparent physical disability or functional
impairment. It can be difficult to care for these patients as
the usual dictum to treat the dyspnea by treating the
underlying disease cannot guide therapy. There is also a
substantial – and growing – population of patients whose
COPD has been maximally treated but who are still
breathless. Patients whose dyspnea cannot be alleviated
through further treatment of their COPD have intractable
dyspnea or refractory dyspnea (Abernethy et al 2003).
There are palliative options that can improve symptoms
and QOL for COPD patients with intractable dyspnea
(Figure 2). The purpose of this review is to outline these
options, discuss the data behind them, and provide practical
guidance. Incorporating this information into clinical
practice first requires that the goals of therapy are clearlyInternational Journal of COPD 2006:1(3) 292
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articulated. We assume here that extending survival is not
the primary goal of therapy. Palliative interventions should
not reduce life expectancy, but can be beneficial even when
they do not extend survival. The therapeutic interventions
will therefore be examined in terms of their impact on relief
of the sensation of breathlessness and/or their impact on
functional status.
Oxygen therapy
Home oxygen therapy is commonly prescribed for patients
with severe COPD. Two randomized controlled trials, one
by the Medical Research Council Working Party (MRCWP
1981) and the other by the Nocturnal Oxygen Therapy Trial
Group (NOTT) (NOTTG 1980), demonstrated that long-
term oxygen therapy (LTOT) prolongs survival in COPD
patients with hypoxemia (PaO2 <55 mmHg). LTOT oxygen
is administered at home for at least 12–15 hours per day. In
the NOTT trial, supplemental criteria for the use of LTOT
in moderately hypoxemic patients (PaO2 55–59 mmHg)
included pulmonary hypertension, cor pulmonale, and
secondary polycythemia (hematocrit ≥55%). These two
studies form the basis on which LTOT is funded by third-
party payers for the management of hypoxemic patients
worldwide. The goal is prolonging survival. The studies do
not focus on symptomatic treatment of dyspnea, improved
function in activities of daily living, and QOL outcomes,
nor do they guide treatment of patients with disabling
dyspnea who are not hypoxemic.
Palliative oxygen is prescribed when the primary goal
is relief of breathlessness. In this setting the data are less
clear. McDonald et al (1995) examined the effects of
palliative oxygen in non-hypoxemic patients with severe
COPD. The effect of medical air vs oxygen on exercise
performance and QOL was examined in a 12-week, double-
 
Ĺ Evidence generally supports use of intervention for the management of refractory dyspnea 
in COPD. 
Ļ Current available evidence does not support use of this intervention. 
ļ Further investigation required. 
Figure 2 Palliative interventions for refractory dyspnea.
Oxygen Pharmacologic Non-pharmacologic
Hypoxemic ↑ Opioids Rehabilitation ↑
Non-hypoxemic ↔ Oral ↑ Nutrition ↔
Parenteral ↑ Psychosocial support ↔
Inhaled ↓ Breathing techniques ↑
Psychotropic drugs Positioning
Anxiolytics ↔ Pursed lip breathing
Phenothiazines ↓ Breathlessness clinics ↔
Selective serotonin reuptake inhibitors ↔
Inhaled furosemide ↔
Heliox ↔International Journal of COPD 2006:1(3) 293
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blind, randomized crossover study involving 26 patients
with severe COPD, mean resting PaO2 69 mmHg (range 58–
82 mmHg), and exertional dyspnea severe enough to
interfere with daily activities. There were small, statistically
significant (p<0.05) increases in 6-minute walk distance with
oxygen. Both oxygen and medical air improved QOL from
baseline but did not affect the sensation of breathlessness.
The authors concluded that there was little evidence to
support prescription of home oxygen for COPD patients
with only mild hypoxemia.
Booth et al (2004) systematically reviewed the published
English-language literature through 2003 regarding the use
of palliative oxygen for the management of breathlessness
in cancer, COPD, and heart failure. They focused on studies
in which breathlessness was measured by intensity scales
such as the visual analog scale (VAS) or Borg scales. Studies
involving the use of supplemental oxygen in patients with
COPD were divided as follows: 1) those investigating the
use of oxygen at rest; 2) those investigating the use of oxygen
before, during and after exercise (ie, “short burst” oxygen
therapy); and 3) those investigating LTOT where
breathlessness was an outcome in addition to survival. A
complete list of the studies included is provided at the end
of this article.
Most of the studies were small (range 5–50 patients)
and poorly controlled. The results were inconsistent and
remarkably patient dependent. The authors concluded that
oxygen at rest may be one part of a palliative treatment plan
for the care of patients with COPD, but that it should be
used only after an “n of 1” assessment as described by Bruera
et al (1992). The goal of the “n of 1” individualized patient
trial is to assess the impact of the oxygen in terms of both
breathlessness and personal QOL. The recommendations
for “short burst” oxygen were similar, reflecting the potential
for some patients to benefit. For example, one study
demonstrated great relief of dyspnea with oxygen for some
participants, although the cumulative results for all patients
in the trial were not statistically significant (Booth et al
1996). Another study showed that dyspnea before and after
exertion in patients with COPD could be relieved (Killen
and Corris 2000). Ambulatory oxygen therapy was
recommended for those that desaturated on exercise but its
continuous use was not as clear cut. Again, the impact of
oxygen needed to be assessed on an individual basis (Eaton
et al 2002). Even those who appeared to derive short-term
benefit may not realize sustained benefit in the long-term
and/or may not wish to continue therapy (Eaton et al 2002).
Oxygen therapy is not without burden; people may have a
sense of being tied to a machine, develop anxiety about
power supply, and limit excursions outside the house.
Despite a lack of convincing evidence for benefit,
palliative oxygen for the management of breathlessness is
commonly prescribed. In a recently reported email survey
of all 648 registered palliative care specialists and respiratory
physicians in Australia and New Zealand (Abernethy et al
2005), 58% of the 214 respondents (69% of palliative
medicine clinicians and 48% of respiratory physicians
surveyed) reported a belief that palliative oxygen is
beneficial and 65% of respondents cited intractable dyspnea
as the most common reason for prescription. Canadian
clinicians reported similar convictions (Stringer et al 2004),
with over 40% of patients receiving LTOT not meeting
current guidelines (Guyatt et al 2000). There is clearly a
need for a definitive randomized trial. We are members of
an international collaborative investigating the role of
palliative oxygen vs medical air for the relief of
breathlessness in patients with intractable dyspnea and PaO2
≥55 mmHg in a definitive, multi-center, randomized, double-
blind controlled trial.
Until these data become available, current evidence
suggests that it is reasonable to prescribe this therapy on a
case by case basis. Our current clinical standard for those
patients who do not enroll in the trial and do not meet criteria
for LTOT is to first establish the goals of therapy in terms
of relief of dyspnea, improvement in function, and
improvement in QOL. Whenever possible we conduct a
blinded “n of 1” trial with oxygen vs air at 2 L/min. A
respiratory therapist or nurse administers the gas, randomly
choosing oxygen or air without revealing the assignment to
the clinician or patient. For practical reasons the gas is
administered for 15 minutes only. The patient undergoes a
5-minute wash-out period and then the other gas is
administered. If access to medical air is not available, the
test can be conducted using a fan as the comparison,
although it will not be blinded. Dyspnea is scored on a VAS
or numerical rating scale (NRS). If function is a major
concern, we conduct a baseline exertional test consistent
with the patient’s best functional status (ie, shuttle test
[Booth and Adams 2001], walking 3 m, reading a
paragraph). The same functional test is repeated after 10
minutes on each gas. Unblinded results are reported to the
clinician and patient. If the patient has superior results on
oxygen, a prescription for palliative oxygen is written after
a careful discussion about the funding for oxygen in the
relevant health system. If air is superior, a fan is prescribed.
If both are equally helpful, then the patient is given the optionInternational Journal of COPD 2006:1(3) 294
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to use whichever he/she prefers. If oxygen is prescribed,
the patient is then asked to evaluate QOL improvements
and limitations related to the therapy over the next week to
ascertain if the intervention should be continued.
Pharmacological interventions
There has been a great deal of interest in treating refractory
dyspnea with non-specific drug therapies aimed at altering
the perception of dyspnea (Burdon et al 1994). Investigators
have looked at oral, parenteral, and inhaled opioids,
psychotropic drugs, inhaled furosemide, and Heliox. A list
of references for each of these interventions is provided at
the end of this article.
Oral and parenteral opioids
The use of opioids in the treatment of refractory
breathlessness has been the subject of investigation for many
years and remains controversial. Most of this revolves
around safety concerns (predominantly respiratory
depression) amidst the perception of inadequate evidence
for the efficacy of opioids in relieving breathlessness in
COPD (Pauwels et al 2001; Currow et al 2003)
The mechanism of action of opioids is poorly understood
and these agents may act centrally, peripherally, or by
reducing anxiety (Leach 2005). It is well known that opioids
reduce ventilatory response to carbon dioxide (Eckenhoff
and Oech 1960), hypoxia (Weil et al 1975; Santiago et al
1977), inspiratory flow-resistive loading (Kryger et al 1976),
and exercise (Santiago et al 1979). Additionally, it is known
that morphine decreases oxygen consumption both at rest
and with exercise in healthy individuals (Santiago et al
1979). These observations led to the evaluation of oral
opioids in individuals with breathlessness due to chronic
airway obstruction. Most of the initial studies conducted
prior to 1998 only included normocapneic individuals
because of concern over respiratory depression. The studies
were small (7–19 patients), used several different opioids
(including dihydrocodeine, codeine, diamorphine,
morphine, and sustained-release morphine) in a variety of
doses, and produced conflicting results. Additionally, most
of the studies were primarily interested in exercise tolerance
as opposed to relief of the sensation of breathlessness and
only one study by Poole et al (1998) assessed QOL as
measured by the Chronic Respiratory Disease Questionnaire
(CRQ).
Two early studies with dihydrocodeine demonstrated
decreased breathlessness with exercise as measured by VAS
as well as increased exercise tolerance as measured by
treadmill or pedometer in the absence of significant adverse
effects (Woodcock et al 1981c; Johnson et al 1983).
However, these early reports were followed by two negative
studies that demonstrated significant adverse effects and
raised the issue of safety (Rice et al 1987; Eiser et al 1991).
Jennings et al (2002) systematically reviewed all data
on the use of opioids through 2001 in an attempt to evaluate
the evidence as a whole. In their assessment of oral and
parenteral opioids, they included eight studies that evaluated
oral morphine, as well as one study that evaluated
subcutaneous morphine. Seven of the nine studies were of
patients with COPD. Meta-analysis demonstrated a highly
statistically significant effect of oral and parenteral opioids
on the sensation of breathlessness (overall pooled effect size
–0.31, 95% confidence internval [CI] –0.50 to –0.13,
p=0.0008). Exercise tolerance was a secondary outcome.
Meta-analysis demonstrated a trend towards an improved
effect on exercise tolerance, but the CI crossed zero (–0.20,
95% CI –0.42 to +0.03, p not stated). The Poole et al (1998)
study found no difference in QOL between treatment and
placebo. Jennings et al (2002) concluded that there was a
definite and highly statistically significant effect of oral or
parenteral opioids on the sensation of breathlessness but
that the clinical effect was relatively small (approximately
8 mm on a 100 mm VAS with baseline levels of dyspnea of
50 mm). They gave several reasons for this small effect,
including that the opioid doses were often small, doses were
not titrated, dosing intervals were long, and single dose
studies would not have achieved steady state. Additionally,
their evaluation of the data did not suggest that the use of
opioids was associated with changes in arterial blood gas
measurements or oxygen saturation.
Following the Jennings et al (2002) systematic review,
Abernethy et al (2003) published results of a trial using oral
morphine in opioid-naïve adults with refractory dyspnea.
Forty-eight outpatients with refractory dyspnea despite
optimal management were enrolled in an adequately
powered 8-day randomized, double-blind, crossover study
in which they received either 20 mg oral morphine sulfate
or placebo. The morphine product used was a 24-hour
sustained-release preparation. The primary outcome was the
sensation of breathlessness measured on a 100 mm VAS;
exercise tolerance was not measured. While participants
were not restricted to those with COPD, 88% had COPD as
the predominant cause of dyspnea. Participants were elderly
(mean age 76, standard deviation [SD] 5) and 71% were on
oxygen. The mean baseline morning dyspnea score was 43
(SD 26). In an intention to treat analysis, there was aInternational Journal of COPD 2006:1(3) 295
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significant decrease in dyspnea with morphine, with mean
improvements in dyspnea intensity of 6.6 mm in the morning
(p=0.011) and 9.5 mm in the evening (p=0.006). Relative
improvement over baseline dyspnea was 15%–22%. These
results were similar to the estimate of efficacy for oral and
parenteral opioids generated by Jennings et al (2002).
Morphine did not depress the respiratory rate (RR; mean
RR for morphine vs placebo = 20 [SD 5] vs 21 [SD 4],
p=0.143) and no episodes of severe sedation or obtundation
were recorded. The main side-effect was constipation (9 vs
1, p=0.021), but neither treatment caused more vomiting,
confusion, sedation, or appetite suppression. Those who
received morphine also described better sleep at night
(p=0.039) despite the fact that the medication was
administered each morning. We concluded that oral
sustained-release morphine could provide relief to patients
with refractory breathlessness, even for patients who were
elderly, had COPD, and were not previously receiving
background opioids. We do caution, however, that this was
not a safety study and was not powered to detect infrequent
significant side-effects, so these agents should be used with
care.
Current data do not clarify the ideal dose of morphine,
the additive effect of opioids, whether all opioids provide
equal effect, or whether the effect would be as substantial
in diseases other than COPD. We used a 20-mg dose of
morphine as that was the lowest dose once daily sustained-
release product available to us at the time of study design.
A dose ranging study exploring 10–30 mg sustained-release
morphine is ongoing. This study will report on long-term
effectiveness and will also clarify whether there is an
additional benefit to increasing the dose sequentially. A study
to evaluate additive effect of additional medication in opioid-
tolerant patients is also planned. In the Jennings et al (2002)
meta-analysis, all of the studies of oral and parenteral opioids
had an effect size in favor of opioids except the two studies
of diamorphine. This suggests that opioids have a beneficial
effect but that all opioids are not the same. A study of
morphine vs oxycodone is also planned. Once adequate data
are available, sub-group analyses considering COPD vs
other causes of dyspnea will be conducted.
In practise, we prescribe oral morphine for COPD
patients with refractory dyspnea. When the patient is opioid-
naïve, we start with a 20-mg, once-daily, sustained-release
morphine preparation if the drug is available and the patient
does not have a contraindication to morphine. When not
available, we start with the 15-mg, twice-daily, long-acting
morphine product, initially prescribing it once a day and
increasing to twice daily after 5–7 days if the patient tolerates
the medication and has residual breathlessness. When the
patient has a contraindication to morphine, we choose long-
acting oxycodone starting at 10 mg once a day and increase
to twice a day after 5–7 days as tolerated and needed. We
have also used hydromorphone dosed around the clock in
analgesic doses equal to 20–30 mg of morphine. We avoid
starting with the 25-µg fentanyl transdermal patch as this
provides over 80 morphine equivalents per day. If an opioid-
tolerant patient is already on a regular dose of morphine or
another opioid, we sequentially increase the opioid by 20%
of the total daily dose every 3–5 days until the breathlessness
is relieved or side-effects occur (Bruera et al 1993).
Nebulized opioids
The role of nebulized opioids in the management of
refractory dyspnea has also been studied. The mechanism
by which these agents may act is currently unclear but it
has been proposed that there may be a direct local effect on
peripheral neural receptors in small airways. Much like the
data with oral opioids, the studies are small and the results
inconsistent. However, on the whole, the majority of studies
failed to demonstrate a benefit, as reported by Jennings et
al (2002) in their meta-analysis. At this point, we do not
feel that there is adequate evidence to support the use of
nebulized opioids in the treatment of refractory
breathlessness. Since the size of nebulized droplets is crucial
for the activity of inhaled opioids, in the future, newer
methods of microdroplet delivery of opioids may result in
rapid systemic effects and improved efficacy of this method
of drug delivery.
Psychotropic drugs
Use of psychotropic agents including anxiolytics,
phenothiazines, and selective serotonin reuptake inhibitors
(SSRIs) for the treatment of refractory dyspnea has received
some attention based on the observation that there is often
a large psychological component to dyspnea and that anxiety
significantly contributes to functional impairment in COPD
(Kim et al 2000). Diazepam was initially reported to be
beneficial by Mitchell-Heggs et al (1980) when they
published the results of an exploratory study in four patients.
However, these results could not be replicated in two
subsequent studies (Woodcock et al 1981a; Sen et al 1983)
which also raised the issue of safety. Several other
investigators chose to re-look at the use of benzodiazepines
but with alprazolam, a shorter-acting and potentially less-
sedating medication. In one controlled study (Man et alInternational Journal of COPD 2006:1(3) 296
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1986), the investigators found no improvement in
breathlessness. However, a benefit was found in a
subsequent single case report (Greene et al 1989).
Anxiolytics
Buspirone, a serotonergic anxiolytic agent, has been shown
to be a respiratory stimulant in animals (Garner et al 1989;
Mendelson et al 1990). Two small studies (Argyropoulou
et al 1993; Singh et al 1993) evaluated the effects of
buspirone on breathlessness, exercise tolerance, and anxiety
in patients with severe COPD. These studies included
slightly different patient populations in that Singh et al
(1993) required baseline anxiety as measured by the
Speilberger State-Trait Anxiety Inventory Scale (STAI) for
study enrollment and Argyropoulou et al (1993) did not
require any baseline anxiety assessment. The results of the
studies conflicted with those of the Argyropoulou et al
(1993) study documenting improvement in all three domains
and the other study finding no difference.
Taken together, these data, while inconsistent, suggest
that there may be a role for anxiolytic agents in selected
patients with refractory dyspnea. Further studies are needed.
In practise, we perform “n of 1” trials for patients where we
plan to use these agents, carefully monitoring for benefit in
terms of relief of the sensation of breathlessness and
improvement in function without overwhelming adverse
effects. When we do not have identical appearing placebos
available, we conduct single-sided “n of 1” trials carefully
documenting outcomes to be reviewed by both clinician and
patient.
Phenothiazines
There are also limited, conflicting data on the use of
phenothiazines. One early study comparing diazepam and
promethazine reported increased exercise tolerance and
decreased breathlessness with promethazine (Woodcock et
al 1981a) but these results were not supported by a
subsequent study (Rice et al 1987). Additionally, the Rice
et al (1987) study raised concerns about side-effects,
including increases in PaCO2 and drowsiness. Light et al
(1996) evaluated both promethazine and prochlorperazine
in combination with morphine in a double-blind, placebo-
controlled study that included seven male patients with
severe COPD (mean FEV1 0.99 L [SD 0.30]). The authors
found that treatment with morphine and promethazine in
combination increased exercise tolerance compared with
placebo (mean increase in workload of 10 W [SD 6.3] vs
1.4 W [SD 6.9], p<0.05). Morphine and prochlorperazine
had an intermediate effect (mean increase in workload of
6.4 W [SD 6.3]; p not reported). The cognitive effects of
both combinations were also assessed. Morphine and
prochlorperazine had a large negative effect on patients’
mental status while morphine and promethazine produced
effects no different from placebo or morphine alone. The
authors suggested that the increased exercise tolerance seen
with the combination of morphine and promethazine was
due to a decreased level of dyspnea at a given workload
despite the fact that there was no significant difference in
Borg scores. Available data, therefore, do not support the
routine use of phenothiazines in the management of
refractory dyspnea, referring to the beneficial effect of
morphine instead.
SSRIs
In recent years, there has been interest in the use of SSRIs
in the treatment of patients with COPD and breathlessness.
A pilot study by Papp et al (1995) reported that six patients
(three of whom had psychiatric disorders) felt better after 6
weeks of sertraline, suggesting that further study was
warranted. Smoller et al (1998) reported a case series of
seven patients with obstructive lung disease treated with
sertraline by their pulmonologists. All patients were
evaluated by a psychiatrist, one in a prospective fashion
using the Structured Clinical Interview for the DSM-III-R
and the other six retrospectively with modules for
depression, dysthymia, panic, agoraphobia, and generalized
anxiety disorder (GAD). Four of the seven patients did not
meet criteria for a psychiatric diagnosis although several
experienced panic and/or anxiety during episodes of
dyspnea. Of the remaining three patients, one met criteria
for panic disorder with agoraphobia, one for both dysthymia
and GAD, and one for major depression. All patients
reported a “decrease” in breathlessness and several also
reported “improvements” in exercise tolerance. There were,
however, no formal measures performed. It is not clear
whether SSRIs improve dyspnea and exercise tolerance by
relieving anxiety symptoms or by direct effects on
respiration. Many patients with dyspnea out of proportion
to their pulmonary compromise experience depression and/
or anxiety and there are data to suggest that treatment of
these symptoms relieves dyspnea (Burns and Howell 1969).
However, there are also animal data suggesting that
serotonin acts at the level of the brainstem respiratory center
and it may be this action that affects the sensation of dyspnea
(Mueller et al 1982). There have been no subsequent studies
of SSRIs and currently there is no substantive evidence onInternational Journal of COPD 2006:1(3) 297
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which to recommend their use in COPD patients with
refractory dyspnea in the absence of an underlying
psychiatric indication. This is an important area for further
study. In patients where there is concern for an underlying
psychiatric disorder (eg, anxiety, depression), there should




There are two additional interventions currently under
investigation. Inhaled furosemide has been studied in
healthy subjects (Nishino et al 2000) and in patients with
COPD (Ong et al 2004). The rationale behind the use of
furosemide includes its inhibitory effect on the cough
response induced by low chloride content solutions
(Ventresca et al 1990) and a preventive effect of furosemide
on bronchoconstriction in asthma (Bianco et al 1988, 1989;
Robuschi et al 1989). Inhaled furosemide may also act
indirectly on vagally mediated sensory nerve ending in
airway epithelium (Chung and Barnes 1992). In healthy
subjects, inhaled furosemide has prolonged breathholding
time and the period of no respiratory sensation and has also
slowed the development of discomfort during loaded
breathing (Nishino et al 2000). Does inhaled furosemide
have a role in the palliation of refractory dyspnea? A
randomized study evaluated the effects of inhaled
furosemide vs placebo in exercise-induced dyspnea (as
assessed by VAS) in 19 patients with moderate to severe
COPD (FEV1 <70%) and moderate-to-severe chronic
breathlessness (Ong et al 2004). Mean dyspnea VAS scores
after exercise were lower after
 inhalation of furosemide
(34mm [SD 25] vs 42 [SD 24], p=0.014). Exercise-related
FEV1 and FVC also improved after furosemide inhalation
(p=0.038 and 0.005, respectively) but not after placebo.
Interestingly, no increase in exercise endurance time was
noted. Both this study and the study by Nishino et al (2000)
suggest that inhaled furosemide deserves further
investigation in the relief of refractory breathlessness.
Heliox28
A second agent that may have a role in the therapy of
refractory breathlessness is Heliox28, a helium–oxygen
mixture containing 72% helium and 28% oxygen. A Phase
II crossover study assessed the palliative role of Heliox28
in 12 lung cancer patients with refractory dyspnea
(Ahmedzai et al 2004). Breathlessness during 6-minute walk
test was evaluated while patients were breathing Heliox28,
28% oxygen, or medical air. The VAS measurements were
significantly lower when comparing Heliox28 with medical
air (40.2% [SD 4.8] vs 59.3% [SD 5.3], p<0.05) but there
was no significant difference between Heliox28 and oxygen
(47.0% [SD 5.6]) or between oxygen and medical air. There
were also no significant differences in Borg scores. Patients
walked farther breathing Heliox28 than breathing oxygen
(214.2 m [SD 9.6] vs 174.6 m [SD 11.2], p<0.05) or medical
air (128.8 m [SD 10.3], p<0.0001). The use of Heliox28 in
the management of COPD has been explored (Grape et al
1960; Ishikawa and Segal 1973; Jaber et al 2000) but there
are no studies evaluating its use in patients with COPD and
refractory dyspnea. The results obtained by Ahmedzai et al
(2004) suggest that further investigation of Heliox28 in the
therapy of COPD patients with refractory dyspnea may be
warranted. Issues of cost and feasibility would need to be




In 1994, “pulmonary rehabilitation” was defined by the
National Institutes of Health Workshop on Pulmonary
Rehabilitation Research as “a multidimensional continuum
of services directed to persons with pulmonary disease and
their families, usually by an interdisciplinary team of
specialists, with the goal of achieving and maintaining the
individual’s maximum level of independence and
functioning in the community” (Fishman 1994 p 826). It is
a well-established component of the care of COPD patients
that is included in the recommendations of most COPD care
guidelines, and there have been numerous studies
demonstrating its value in reducing dyspnea, improving
QOL, and increasing independence–exercise capacity
(Lacasse et al 1996; Guell et al 2000). There is also an
evidence-based guideline examining its scientific basis
(ACCP/AACVPR 1997). Pulmonary rehabilitation is
typically introduced early in the illness trajectory so, while
it certainly has a role in the care of patients with advanced
COPD, a detailed exploration of the data supporting its use
is beyond the scope of this review.
Nutrition
Malnutrition is not uncommon in patients with COPD and
weight loss can become particularly severe as the disease
advances. Consequences of this loss include weakness of
inspiratory and expiratory muscles which can lead toInternational Journal of COPD 2006:1(3) 298
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impaired lung function (Wilson et al 1986). Studies have
demonstrated a link between malnutrition and impaired
pulmonary status (Sahebjami et al 1993) as well as with
increased mortality (Wilson et al 1989). It therefore stands
to reason that nutritional support would constitute a simple,
effective intervention in the management of patients with
severe COPD. The data, however, do not support this idea.
Ferreira et al (2005) performed a meta-analysis of eleven
randomized, controlled trials looking at the effects of
nutritional supplementation in patients with severe COPD.
All studies evaluated the use of liquid oral supplements,
including Pulmocare
® (Ross Laboratories, Columbus, OH,
USA), Build-up
® (Nestle, Croydon, Surrey, UK), Sustacal®
(Mead Johnson Nutritionals, Bristol Myers Squibb, New
York, NY, USA), Isocal
® (Mead Johnson Nutritionals,
Bristol Myers Squibb, NY, NY, USA), and Respifor
®
(Nutricia, Zoetermeer, Netherlands). Ferreira et al (2005)
identified no significant effect on any outcome variable,
including anthropomorphic measures, pulmonary function,
respiratory muscle strength, functional exercise capacity,
and health-related QOL. Because only 3 (Efthimiou et al
1988;Otte et al 1989;Steiner et al 2003) of the 11 studies
evaluated QOL or dyspnea, it is difficult to draw conclusions
regarding the effect of nutrition on outcomes most important
to patients with end-stage COPD who require palliation. A
well-designed clinical trial of nutritional supplementation
in end-stage COPD patients with dyspnea and reduced QOL
would be useful to assess the effects of this simple
intervention.
Psychosocial support
Providing support is a fundamental part of caring for any
patient with chronic illness, but it becomes more important
as patients begin to decline and experience more functional
limitations. Patients often need help coping with their illness
and the changes occurring in their lives. At the same time,
relatives and family members may require support as
relationships and family roles change as a result of disease
progression and increasing symptom burden (Leach 2005).
There are several qualitative studies that highlight the
specific need for support of those caring for individuals with
breathlessness. Booth et al (2003) sought to investigate the
experience of living with breathlessness both in patients with
cancer or COPD and in those individuals providing informal
care. The investigators interviewed 10 COPD patients and
their caregivers in their homes; 30% of interviews were
conducted separately. Six of the patients were male; they
were all Caucasian and ranged in age from 51 to 80 years
(mean = 70 years). The study found that many caregivers
found taking care of a breathless person to be “pre-
occupying, restricting, and a major cause of anxiety” (Booth
et al 2003 p 341). Anxiety was noted to be particularly bad
a night and several caregivers described spending time
listening to their spouse breathing. The investigators
concluded that clinicians must not forget about the needs of
their patients’ families and that patients with disabling
symptoms are often best cared for using a multidisciplinary
approach. A similar study described the experiences of 10
patients with COPD and their caregivers (Seamark et al
2004). The caregivers were married to the patient in seven
of the 10 cases and ranged in age from 60 to 93 years (mean
72 years). They expressed losses similar to those of the
patients and felt burdened by the multiple roles that they
were forced to fulfill. There was also a sense that it was not
fair that the illness affected both patient and caregiver and
this often contributed to tension in the relationships.
There are no specific guidelines available regarding
specific support for either patients or their informal
caregivers. Clinicians caring for these patients must be
conscious of the potential need for increased support as well
as responsive to patient–family concerns when they arise.
To date there have been no reports of systematic evaluation
of isolated behavioral or psychosocial interventions for
COPD patients with intractable dyspnea. This is an important
area for future study.
Breathing techniques
Several controlled breathing techniques including
positioning and pursed lip breathing (PLB) are useful in
the management of breathlessness. The most commonly used
position is one in which the patient leans forward and
supports his/her weight with the arms–upper body. This
serves to increase abdominal pressure and may improve
respiratory muscle function (ATS 1999). Use of the leaning
forward position has also been reported to improve
inspiratory muscle strength (O’Neill and McCarthy 1983)
and diaphragmatic function (Sharp et al 1980), reduce the
use of accessory muscles, and decrease abdominal breathing
(Barach and Beck 1954; Barach 1974; Sharp et al 1980).
PLB involves inhalation through the nose followed by a
slow exhalation, usually 4–6 seconds, through pursed lips.
It has been shown to decrease air trapping by stenting the
airways and preventing dynamic airway collapse (Tiep et
al 1986) and often helps to avert panic attacks that
accompany severe breathlessness (Madge and Edmond
2001). Unfortunately, despite studies demonstrating theInternational Journal of COPD 2006:1(3) 299
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benefit of these techniques in relieving dyspnea, the results
in practice are variable (ATS 1999). In practise, instruction
in positioning and PLB is provided to all of our patients
with dyspnea, and the skills reviewed during subsequent
clinic visits.
Breathlessness clinics
“Breathlessness clinics” are another potential intervention
for dyspneic patients with advanced COPD. Nurse
practitioners who run these clinics lead weekly sessions that
focus on counseling, breathing re-training, relaxation, and
coping–adaptation strategies for dealing with breathlessness.
The “breathlessness clinic” model combines education and
psychosocial support, and has thus far focused on patients
with lung cancer.
The initial pilot study demonstrating benefit of these
clinics was published in 1996 (Corner et al 1996). It involved
34 lung cancer patients with breathlessness randomized to
the nursing intervention or control. The intervention group
attended weekly 1-hour sessions for 3–6 weeks. During these
sessions, the nurse practitioner assessed patients’
breathlessness, disease, and feelings. He/she gave advice
and support about managing breathlessness, including
activity pacing, as well as education on breathing and
relaxation techniques. The control group was encouraged
to talk about their disease but received no counseling or
breathing training. Outcomes were assessed at baseline, one
month and three months by three separate VAS scales, the
Functional Capacity Scale, and the HADS. The study
stopped recruiting at 34 patients at the request of the clinic
staff who noted benefit in the intervention group. Despite
the small number of participants and the loss of 14 patients,
leaving only 20 patients for analysis, 3 months after study
entry the intervention group saw significant improvements
in worst breathlessness (p=0.02), distress caused by
breathlessness (p=0.02), and functional capacity (p=0.03).
Symptoms in the control group either remained static or
worsened over the course of the study.
Two subsequent studies (Bredin et al 1999; Hately et al
2003) have further validated this concept. In a multicenter
study involving 119 patients, Bredin et al (1999) found
similar improvements in breathlessness at best (p=0.03),
performance status (p=0.02), depression (p=0.02), physical
symptoms (p=0.04), and activity (ie, climbing stairs, walking
outdoors, and going shopping, p=0.05). A smaller study by
Hately et al (2003) of 30 breathless patients with lung cancer
also demonstrated improvements. The authors saw a
decrease in frequency of respiratory symptoms (p<0.001)
as well as an improvement in functional capacity (p<0.001)
and QOL scores, with the greatest improvement in “patients’
ability to do what they want” (p=0.001) and in overall QOL
(0.004). Breathlessness scores were improved with
significant reductions in VAS scores for breathing at best
(median reduction = 1, p=0.001), breathing at worst (median
reduction = 3, p<0.001) and distress caused by breathing
(median reduction = 4, p<0.001). Qualitative data
demonstrated the value of the intervention on patient’s
adjustment to their cancer diagnosis as well as their sense
of well-being.
These three studies (Corner et al 1996; Bredin et al 1999;
Hately et al 2003) suggest a role for a nursing intervention
incorporating psychosocial support and education in the care
of breathless patients with lung cancer. There no studies
evaluating such an intervention in patients with end-stage
COPD, though this is a population that would likely derive
similar benefit. Practically, patients with lung cancer and
COPD may be referred to a “breathlessness clinic” when
such a specialty clinic is available. However, these types of
tertiary referral clinics are often not the ideal setting to see
a sick patient and his/her family on a regular basis, so
continued follow-up by the referring physician with attention
to continued symptom management is required. Future goals
should focus on evaluating this model in other diseases and
developing sustainable models that can be rolled out
worldwide.
Conclusions and future directions
COPD is a common disease with a course that deteriorates
in a relentless fashion until culminating in severe functional
limitation and symptom burden. Intractable or refractory
dyspnea is a substantial contributor to this suffering. As
individuals continue to live longer, the number of “end-
stage” COPD patients will increase. Their needs are similar
to those of lung cancer patients but COPD patients are
offered and use fewer palliative interventions. The reason
for this is not clear but it may be due, at least in part, to a
differential focus of the individuals caring for these two
groups of patients. Palliative interventions for patients with
advanced COPD have the potential to reduce the suffering
caused by breathlessness. The goal of palliative interventions
in “end-stage” disease is to decrease symptoms, and improve
functional status and QOL.
In this paper we have outlined the interventions currently
available for the global treatment of refractory dyspnea. Oral
or parenteral opioids are beneficial with the most evidence
available for morphine. Palliative oxygen may be beneficialInternational Journal of COPD 2006:1(3) 300
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for some patients; an “n of 1” trial is the best approach until
further information is available. Anxiolytics and SSRIs have
limited and sometimes conflicting data; they should be
approached cautiously and with explicit expected outcomes
until more information is available. Inhaled furosemide is
an interesting potential intervention that needs more study.
Heliox28 may or may not be beneficial but its use may be
most limited by feasibility concerns. Nutrition needs further
study, as does counseling, behavioral therapies, and
breathlessness clinics for COPD. Instruction in positioning
and PLB is a simple intervention with potential to be very
effective but without prior systematic study. Maintaining
physical activity, whether via a structured pulmonary
rehabilitation program or via another intervention, remains
an important intervention, albeit one that is less well studied
in individuals with refractory breathlessness.
It is clear that there is more work to be done as many of
the options have little or limited evidence to support their
use. We have tried to identify areas that are currently under
investigation as well as those that require further exploration.
We are currently involved in a multi-center, randomized
clinical trial investigating the role of palliative oxygen vs
medical air in non-hypoxemic patients with intractable
dyspnea. Additionally, there is an ongoing study evaluating
varying doses of sustained-release morphine. A study of
newer psychotropic agents is planned. Finally, non-
pharmacologic interventions such as breathlessness clinics
have proven benefit in lung cancer patients but need specific
evaluation in COPD.
All of this translates to the needs for better palliative
care for patients with advanced COPD and for the difficult
problems that create suffering like refractory dyspnea.
Whether this care is best provided by the patient’s long-
standing primary care provider or pulmonologist with or
without specialist palliative care support or by primary
palliative care teams who take over care remains to be seen.
Hospices, inpatient palliative care units, and symptom
management consults are also important supports for the
care of the COPD patient with unrelenting dyspnea.
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Selected reference list
Studies included in Booth et al (2004)
systematic review
Use of oxygen at rest: (Liss and Grant 1988; Swinburn et al
1991; Booth et al 1996; O’Donnell et al 2001)
Use of oxygen before, during and after exercise (ie “short
burst” oxygen therapy): (Woodcock et al 1981b; Waterhouse
and Howard 1983; Swinburn et al 1984; Evans et al 1986;
Lane et al 1987; Davidson et al 1988; McKeon et al 1988a,
1988b; Kollef and Johnson 1990; Dean et al 1992; Leach et
al 1992; Dewan and Bell 1994; Roberts et al 1996;
O’Donnell et al 1997; Marques-Magallanes et al 1998;
Killen and Corris 2000; Knebel et al 2000; Revill et al 2000;
Jolly et al 2001; Maltais et al 2001; O’Donnell et al 2001;
Somfay et al 2001; Eaton et al 2002)
Use of LTOT where breathlessness was an outcome in
addition to survival: (McDonald et al 1995; Rooyackers et
al 1997; Garrod et al 2000; Eaton et al 2002)
Studies on pharmacologic interventions
Opiods – oral: (Woodcock et al 1981c; Johnson et al 1983;
Rice et al 1987; Light et al 1989, 1996; Eiser et al 1991;
Poole et al 1998; Jennings et al 2002; Abernethy et al 2003)
Opioids – parenteral: (Bruera et al 1993)
Opiods – inhaled: (Young et al 1989; Beauford et al 1993;
Farncombe et al 1994; Harris-Eze et al 1995; Masood et al
1995; Leung et al 1996; Jankelson et al 1997; Noseda et al
1997; Jennings et al 2002; Foral et al 2004)
Psychotropic agents – anxiolytics: (Mitchell-Heggs et al
1980; Woodcock et al 1981a; Sen et al 1983; Eimer et al
1985; Man et al 1986; Greene et al 1989; Argyropoulou et
al 1993; Singh et al 1993)
Psychotropic agents – phenothiazines: (Woodcock et al
1981a; O’Neill et al 1985)
Psychotropic agents – SSRIs: (Papp et al 1995; Smoller et
al 1998)
Inhaled furosemide: (Nishino et al 2000; Ong et al 2004)
Heliox28: (Ahmedzai et al 2004).International Journal of COPD 2006:1(3) 301
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Studies included in Jennings et al (2002)
systematic review
Studies evaluating oral morphine: (Woodcock et al 1981c,
1982; Johnson et al 1983; Eiser et al 1991; Light et al 1996;
Chua et al 1997; Poole et al 1998)
Study evaluating subcutaneous morphine: (Bruera et al
1993).
Studies evaluating inhaled morphine: (Young et al 1989;
Beauford et al 1993; Davis et al 1994, 1996; Harris-Eze et
al 1995; Masood et al 1995; Leung et al 1996; Jankelson et
al 1997; Noseda et al 1997)
Studies included in Ferreira et al (2005)
meta-analysis
(Lewis et al 1987; Efthimiou et al 1988; Knowles et al 1988;
Otte et al 1989; Fuenzalida et al 1990; Whittaker et al 1990;
DeLetter 1991; Schols et al 1995; Steiner et al 2002a, 2002b,
2003; Goris et al 2003)
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